Christopher Harlan, DO
Family Medicine · Kansas City, MONPI 1619182052
Payments from drug & device makers
Across 476 payments — averaging $15.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$794
- Lilly USA, LLC$702
- Novo Nordisk$593
- Abbott$530
- Pfizer$520
- plus $3K from 34 others
What the payments were for
- Food & beverage$7,482100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 63 | $1,195 |
| AbbVie(2 entities) | 60 | $794 |
| Lilly USA, LLC | 45 | $702 |
| Novo Nordisk | 44 | $593 |
| Abbott | 27 | $530 |
| Pfizer | 46 | $520 |
| Boehringer Ingelheim | 23 | $373 |
| Amgen | 22 | $329 |
| GSK | 21 | $319 |
| Otsuka America Pharmaceutical, Inc. | 13 | $246 |
| Antares Pharma, Inc. | 10 | $172 |
| Dexcom, Inc. | 9 | $166 |
| Sumitomo Pharma America, Inc. | 10 | $133 |
| Eisai Inc. | 7 | $130 |
| Astellas Pharma US Inc | 5 | $123 |
| Exact Sciences | 7 | $116 |
| E.r. Squibb & Sons, L.L.C. | 8 | $115 |
| Supernus Pharmaceuticals, Inc. | 6 | $113 |
| Merck | 7 | $101 |
| Johnson & Johnson | 6 | $96 |
| Axsome Therapeutics, Inc. | 5 | $78 |
| Phathom Pharmaceuticals, Inc. | 4 | $75 |
| Kowa Pharmaceuticals America, Inc. | 3 | $44 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $38 |
| IBSA Pharma Inc. | 2 | $36 |
| Neurelis, Inc. | 2 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Halozyme Inc | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| Bayer | 2 | $31 |
| Vertex | 1 | $29 |
| Sunovion Pharmaceuticals Inc. | 2 | $27 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Tolmar, Inc. | 1 | $19 |
| Alkermes, Inc. | 1 | $19 |
| Inogen, Inc. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Boston Scientific | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,494 in reported general payments places this provider in the 90th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 103 | $109,583 |
| OzempicSemaglutide | 45 | $70,790 |
| MounjaroTirzepatide | 37 | $65,396 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 76 | $58,197 |
| JardianceEmpagliflozin | 32 | $52,797 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $26,143 |
| MyrbetriqMirabegron | 30 | $19,466 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 16 | $13,272 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 39 | $12,415 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 35 | $7,662 |
| Spiriva RespimatTiotropium Bromide | 11 | $7,650 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $7,228 |
| Atorvastatin Calcium | 468 | $5,374 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $5,087 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,753 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $520 | $121,998142 claims |
| Novo NordiskOzempic | $593 | $70,79045 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,195 | $65,425102 claims |
| Lilly USA, LLCMounjaro | $702 | $65,39637 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $373 | $60,44843 claims |
| GSKTrelegy Ellipta, Shingrix, Breo Ellipta | $319 | $38,55876 claims |
| Astellas Pharma US IncMyrbetriq | $123 | $19,46630 claims |
| AbbVieSynthroid | $794 | $1,52615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Kansas City
- Scott KuennenKansas City$2.2M
- Blair ThedingerKansas City$1.3M
- Heather JordanKansas City$70K
- Jon MattsonKansas City$53K
- Meredith LevineKansas City$26K
- Cindy ChangKansas City$22K
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.